‘Right To Try’ Legislation Will Do More Harm Than Good, Patient Advocacy Groups Warn Congress
More than three dozen groups say that the framework of FDA's compassionate use program is already in place to help terminal patients access experimental drugs.
40 Patient Advocacy Groups Oppose 'Right To Try' Drug Bill
Nearly 40 patient advocacy groups told House leaders they opposed the "right to try" bill on experimental drugs, arguing the measure would “likely do more harm than good.” In a letter sent to the House leaders of both parties, the groups wrote that they believe the right to try legislation wouldn’t actually lead to greater patient access to unapproved drugs and that the current regulatory framework exists so patient protections aren’t undermined. (Roubein, 2/6)
'Right To Try' Advocates Concerned About Potential Bill Changes
House leaders could alter legislation meant to expand access to experimental drug treatments for terminally ill patients, raising concerns among lawmakers who are working on the issue. Energy and Commerce Committee Chair Greg Walden, R-Ore., told reporters this week that the House could make the Senate-passed measure (S 204) “even better” before considering the bill, which has stalled in the House since passing the Senate by voice vote in August. The measure, known by supporters as “Right to Try” legislation, appears to have new momentum after President Donald Trump called for its passage during the State of the Union address last week. (McIntire, 2/6)